Table 4

Objective responses (12 evaluable patients)

Response (WHO)Irinotecan dose (mg/m2/day)
Overall20.022.525.0
n(%)nnn
Complete0
Partial3(25%)3
Minor2(17%)11
Stable4(33%)22
Progression3(25%)12